Subcutaneous delivery of amivantamab in patients with advanced solid malignancies: Initial safety and pharmacokinetic results from the PALOMA study.

被引：0
|
作者：
Krebs, Matthew G. [1 ,2 ]
Johnson, Melissa L. [3 ]
Cho, Byoung Chul [4 ]
Lee, Se-Hoon [5 ]
Kudgus-Lokken, Rachel [6 ]
Zemlickis, Donna [7 ]
Mitselos, Anna [8 ]
Berkay, Eileen [6 ]
Bauml, Joshua M. [6 ]
Knoblauch, Roland E. [6 ]
Hellemans, Peter [8 ]
Minchom, Anna [9 ]
机构：
[1] Univ Manchester, Div Canc Sci, Fac Biol Med & Hlth, Manchester, Lancs, England
[2] Christie NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England
[3] Sarah Cannon Res Inst, Nashville, TN USA
[4] Yonsei Univ, Yonsei Canc Ctr, Coll Med, Seoul, South Korea
[5] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
[6] Janssen R&D, Spring House, PA USA
[7] Janssen R&D, Toronto, ON, Canada
[8] Janssen R&D, Beerse, Belgium
[9] Royal Marsden Inst Canc Res, Drug Dev Unit, Sutton, Surrey, England
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT198
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Subcutaneous delivery of amivantamab in patients with advanced solid malignancies: PALOMA, an open-label, multicenter, dose escalation phase 1b study.
    Krebs, Matthew
    Johnson, Melissa Lynne
    Cho, Byoung Chul
    Park, Keunchil
    Haddish-Berhane, Nahor
    Zemlickis, Donna
    Mitselos, Anna
    Meacle, Francis
    Knoblauch, Roland Elmar
    Hellemans, Peter
    Minchom, Anna Rachel
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] Subcutaneous amivantamab (ami) in patients (pts) with advanced solid malignancies: The PALOMA study-Updated safety and identification of the recommended phase 2 dose
    Minchom, Anna Rachel
    Krebs, Matthew G.
    Cho, Byoung Chul
    Lee, Se-Hoon
    Leighl, Natasha B.
    O'Neil, Bert
    Sabari, Joshua K.
    Kudgus-Lokken, Rachel
    Alhadab, Ali
    Haddish-Berhane, Nahor
    Zemlickis, Donna
    Mitselos, Anna
    Berkay, Eileen
    Bauml, Joshua Michael
    Knoblauch, Roland E.
    Hellemans, Peter
    Johnson, Melissa Lynne
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] Subcutaneous vs Intravenous Amivantamab: Patient Satisfaction and Resource Utilization Results from the PALOMA-3 Study
    Alexander, M.
    Cheng, Y.
    Lee, S. -H.
    Passaro, A.
    Spira, A. I.
    Cho, B. C.
    Lim, S. M.
    Ohe, Y.
    Nagrial, A.
    Tan, J. L.
    Wainsztein, V.
    Ramos, E.
    Garcia Campelo, M. del Rosario
    Akamatsu, H.
    Nguyen, D.
    Cortot, A. B.
    Zer, A.
    Erdem, D.
    Sanborn, R. E.
    Emde, T. -O.
    Minchom, A. R.
    Zurawski, B.
    Ferreira, M. L.
    Yang, J. C. -H.
    Marmarelis, M. E.
    Schuchard, J.
    Alves, J.
    Ghosh, D.
    Verheijen, R. B.
    Gamil, M.
    Bauml, J. M.
    Baig, M.
    Leighl, N. B.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S29 - S29
  • [4] Subcutaneous amivantamab and lazertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Results from the phase 2 PALOMA-2 study.
    Lim, Sun Min
    Tan, Jiunn-Liang
    Dias, Josiane Mourao
    Voon, Pei Jye
    How, Soon Hin
    Zhou, Xiangdong
    Xiong, Hailin
    Massuti, Bartomeu
    Medley, Louise C.
    Nagasaka, Misako
    Vicente, David
    Girard, Nicolas
    Rittmeyer, Achim
    Botesteanu, Dana-Adriana
    Alhadab, Ali
    Mahoney, Janine M.
    Zhang, Jie
    Bauml, Joshua Michael
    Baig, Mahadi
    Scott, Susan Combs
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA8612 - LBA8612
  • [5] Comparing subcutaneous vs intravenous amivantamab with lazertinib in EGFR-mutated advanced NSCLC: Analysis of Asian patients from PALOMA-3
    Lee, S-H.
    Akamatsu, H.
    Yang, J. C-H.
    Lim, S. M.
    Liu, B.
    John, T.
    Wang, J.
    Ohe, Y.
    Kondo, M.
    Tamiya, M.
    Danchaivijitr, P.
    Hsu, P-C.
    Zhuo, J.
    Saadoun, C.
    Saxena, N.
    Balaburski, G.
    Ribeiro, L.
    Gamil, M.
    Baig, M.
    Cheng, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S1634 - S1634
  • [6] A phase Ib safety and pharmacokinetic study of bavituximab plus chemotherapy in patients with refractory advanced solid tumor malignancies
    Digumarti, R.
    Bapsy, P. P.
    Shan, J. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [7] Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies
    Argiris, Athanassios
    Feinstein, Trevor M.
    Wang, Lin
    Yang, Tianbing
    Agrawal, Shruti
    Appleman, Leonard J.
    Stoller, Ronald G.
    Grandis, Jennifer R.
    Egloff, Ann Marie
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (04) : 1575 - 1584
  • [8] A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies
    Britten, CD
    Rowinsky, EK
    Baker, SD
    Agarwala, SS
    Eckardt, JR
    Barrington, R
    Diab, SG
    Hammond, LA
    Johnson, T
    Villalona-Calero, M
    Fraass, U
    Statkevich, P
    Von Hoff, DD
    Eckhardt, SG
    CLINICAL CANCER RESEARCH, 1999, 5 (07) : 1629 - 1637
  • [9] Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies
    Athanassios Argiris
    Trevor M. Feinstein
    Lin Wang
    Tianbing Yang
    Shruti Agrawal
    Leonard J. Appleman
    Ronald G. Stoller
    Jennifer R. Grandis
    Ann Marie Egloff
    Investigational New Drugs, 2012, 30 : 1575 - 1584
  • [10] A phase I and pharmacokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignancies
    Rowinsky, Eric K.
    Beeram, Muralidhar
    Hammond, Lisa A.
    Schwartz, Garry
    De Bono, Johann
    Forouzesh, Baharam
    Chu, Quincy
    Latz, Jane E.
    Hong, Shengyan
    John, William
    Nguyen, Binh
    CLINICAL CANCER RESEARCH, 2007, 13 (02) : 532 - 539
12345